Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Immunomedics
Pharma
Gilead sees 33% of revenue coming from oncology drugs in 2030
In a presentation, Gilead said it plans to derive a third of its revenue from oncology products by 2030, requiring a major portfolio transformation.
Kevin Dunleavy
Apr 18, 2022 3:15pm
Immunomedics will settle claims it misrepresented Trodelvy data
Apr 18, 2022 11:06am
Gilead's East Coast hub in New Jersey will employ up to 500
Mar 25, 2022 10:24am
Gilead CEO Daniel O'Day scores $19M in 2021 compensation
Mar 25, 2022 9:32am
Gilead Sciences will lay off 114 staffers in NJ
Mar 8, 2022 12:08pm
Gilead's Immunomedics joins Olivia Newton-John for cancer push
Jan 8, 2021 5:33pm
